Author

Yazan M. Alsayed

Observed names: Alsayed Yazan, Y AlSayed, Y Alsayed, Y. Alsayed, Yazan Al Sayed, Yazan Alsayed

Observed institutions: Northwestern University, United States Department of Veterans Affairs, University of Pittsburgh, University of Rochester Medicine, University of Illinois Chicago, Cancer Research And Biostatistics, UPMC Hillman Cancer Center, Jesse Brown VA Medical Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Rochester, University of Arkansas for Medical Sciences

OpenAlex ID: A5110085052

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

2006 · John D. Shaughnessy, Fenghuang Zhan, et al. · Blood · 915

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma

2006 · Yazan Alsayed, Hai Ngo, et al. · Blood · 478

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

2012 · S. Z. Usmani, C. Heuck, et al. · Haematologica · 394

PDF

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

2007 · Bart Barlogie, Elias Anaissie, et al. · British Journal of Haematology · 331

PDF

Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons

1999 · Shahab Uddin, Beata Majchrzak, et al. · Journal of Biological Chemistry · 227

PDF

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

2008 · Bart Barlogie, Mauricio Pineda-Roman, et al. · Blood · 225

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

2010 · Bijay Nair, Frits van Rhee, et al. · Blood · 201

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

2010 · Yiming Zhou, Lijuan Chen, et al. · Proceedings of the National Academy of Sciences · 190

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

2007 · Frits van Rhee, Vanessa Bolejack, et al. · Blood · 184

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

2011 · John D. Shaughnessy, Pingping Qu, et al. · Blood · 176

Interferon-α Resistance in a Cutaneous T-Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression

1998 · Wenn H. Sun, Carlos Pabon, et al. · Blood · 169

Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to All-trans-retinoic Acid

2001 · Yazan Alsayed, Shahab Uddin, et al. · Journal of Biological Chemistry · 161

PDF

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

2008 · Bart Barlogie, Elias Anaissie, et al. · Cancer · 121

PDF

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

2012 · S Z Usmani, J Crowley, et al. · Leukemia · 114

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

2010 · Frits van Rhee, Jackie Szymonifka, et al. · Blood · 108

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

2008 · Bart Barlogie, Frits van Rhee, et al. · Blood · 102

The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein

1997 · Sarfraz Ahmad, Yazan M. Alsayed, et al. · Journal of Biological Chemistry · 102

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

2007 · Jeffrey Haessler, John D. Shaughnessy, et al. · Clinical Cancer Research · 101

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

2009 · Antje Hoering, John Crowley, et al. · Blood · 100

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia

2007 · Anne-Sophie Moreau, Xiaoying Jia, et al. · Blood · 98

Engagement of Gab1 and Gab2 in Erythropoietin Signaling

1999 · Amittha Wickrema, Shahab Uddin, et al. · Journal of Biological Chemistry · 97

PDF

Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma

2006 · Lanie K. Francis, Yazan Alsayed, et al. · Clinical Cancer Research · 91

PDF

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

2012 · S Z Usmani, B Nair, et al. · Leukemia · 84

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

2012 · Saad Z. Usmani, Rachel Sexton, et al. · Blood · 75

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

2007 · Bart Barlogie, Guido Tricot, et al. · Blood · 74

PDF

Works count: 108

Citation count: 5,528

H-index: 33

I10-index: 39